Recurrent epithelial ovarian carcinoma : a randomized phase III study of pegylated liposomal doxorubicin versus topotecan . 
<br>
<br> PURPOSE To compare the efficacy and safety of pegylated liposomal doxorubicin ( PLD ) and topotecan in <font color="blue">patients_6</font> <font color="blue">with_6</font> <font color="blue">epithelial_6</font> <font color="blue">ovarian_6</font> <font color="blue">carcinoma_6</font> <font color="blue">that_4</font> <font color="blue">recurred_4</font> <font color="blue">after_4</font> <font color="blue">or_4</font> <font color="blue">did_4</font> <font color="blue">n't_4</font> <font color="blue">respond_4</font> <font color="blue">to_4</font> <font color="blue">first_4</font> <font color="blue">-_4</font> <font color="blue">line_4</font> <font color="blue">,_4</font> <font color="blue">platinum_4</font> <font color="blue">-_4</font> <font color="blue">based_4</font> <font color="blue">chemotherapy_4</font> <font color="blue">._4</font> <font color="blue">
<br>_1</font> PATIENTS AND METHODS <font color="blue">Patients_6</font> <font color="blue">with_6</font> <font color="blue">measurable_6</font> <font color="blue">and_6</font> <font color="blue">assessable_6</font> <font color="blue">disease_6</font> were randomized to receive either PLD 50 mg / m(2 ) as a 1-hour infusion every 4 weeks or topotecan 1.5 mg / m(2)/d for 5 consecutive days every 3 weeks . <font color="blue">Patients_1</font> <font color="blue">were_1</font> <font color="blue">stratified_1</font> <font color="blue">prospectively_1</font> <font color="blue">for_1</font> <font color="blue">platinum_1</font> <font color="blue">sensitivity_1</font> <font color="blue">and_1</font> <font color="blue">for_1</font> <font color="blue">the_1</font> <font color="blue">presence_1</font> <font color="blue">or_1</font> <font color="blue">absence_1</font> <font color="blue">of_1</font> <font color="blue">bulky_1</font> <font color="blue">disease_1</font> <font color="blue">._1</font> 
<br> RESULTS <font color="blue">A_3</font> <font color="blue">total_3</font> <font color="blue">of_3</font> <font color="blue">474_7</font> <font color="blue">patients_7</font> <font color="blue">were_3</font> <font color="blue">treated_3</font> <font color="blue">(_2</font> <font color="blue">239_2</font> <font color="blue">PLD_2</font> <font color="blue">and_2</font> <font color="blue">235_2</font> <font color="blue">topotecan_2</font> <font color="blue">)_2</font> <font color="blue">._2</font> They comprised the intent - to - treat population . The overall progression - free survival rates were similar between the two arms ( P = .095 ) . The overall response rates for PLD and topotecan were 19.7% and 17.0% , respectively ( P = .390 ) . Median overall survival times were 60 weeks for PLD and 56.7 weeks for topotecan . Data analyzed in platinum - sensitive patients demonstrated a statistically significant benefit from PLD for progression - free survival ( P = .037 ) , with medians of 28.9 for PLD versus 23.3 weeks for topotecan . For overall survival , PLD was significantly superior to topotecan ( P = .008 ) , with a median of 108 weeks versus 71.1 weeks . The <font color="blue">platinum_1</font> <font color="blue">-_1</font> <font color="blue">refractory_1</font> <font color="blue">subgroup_1</font> demonstrated a nonstatistically significant survival trend in favor of topotecan ( P = .455 ) . Severe hematologic toxicity was more common with topotecan and was more likely to be associated with dosage modification , or growth factor or blood product utilization . 
<br> CONCLUSION The comparable efficacy , favorable safety profile , and convenient dosing support the role of PLD as a valuable treatment option in this patient population .